Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
LM22B 10 is a TrkB and TrkC agonist. Exhibits neurotrophic activity (EC50 = 200-300 nM), improves survival and increases neurite outgrowth in hippocampal cells in vitro. Exhibits no significant activity in a screen of 57 other receptors and transporters. Inhibits binding of BDNF and neurotrophin-3 to TrkB and TrkC, respectively. Active in vivo and brain penetrant.
LM22B 10 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 485.02. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.06 mL||10.31 mL||20.62 mL|
|5 mM||0.41 mL||2.06 mL||4.12 mL|
|10 mM||0.21 mL||1.03 mL||2.06 mL|
|50 mM||0.04 mL||0.21 mL||0.41 mL|
References are publications that support the biological activity of the product.
Yang et al (2016) A small molecule TrkB/TrkC neurotrophin receptor co-activator with distinctive effects on neuronal survival and process outgrowth. Neuropharmacology 110 343 PMID: 27334657
If you know of a relevant reference for LM22B 10, please let us know.
Keywords: LM22B 10, LM22B 10 supplier, LM22B10, trkB, trkC, agonists, agonism, neurotrophins, neurotrophic, brain, penetrant, Trk, Receptors, 6037, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for LM22B 10 include:
Tigaret et al (2021) Neurotrophin receptor activation rescues cognitive and synaptic abnormalities caused by hemizygosity of the psychiatric risk gene Cacna1c. Mol Psychiatry 26 1748 PMID: 33597718
Do you know of a great paper that uses LM22B 10 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review LM22B 10 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.